Structure-Guided Discovery of WRN Inhibitors for MSI-H Tumors

A dataset from figshare, authored by Qibang Sui and last updated on June 3, 2026, describes the discovery of Werner Syndrome RecQ Helicase (WRN) inhibitors. It details the rational design of two compound classes, spirocyclic compounds and benzo-fused heterocyclic analogs, and the in vitro and in vivo evaluation of a lead candidate named Q15. The dataset includes results on potency, selectivity, oral pharmacokinetics, and antitumor efficacy in models of microsatellite instability-high tumors.

Use Cases

• Comparing in vitro activity and cellular selectivity of novel WRN inhibitors based on the described compound classes.
• Analyzing oral pharmacokinetic properties of drug candidates relative to a benchmark compound (HRO761).
• Evaluating antitumor efficacy and dose-response relationships in preclinical models of MSI-H tumors.
• Assessing preliminary safety profiles of novel small-molecule inhibitors for oncology applications.

Strengths

• The description provides specific, named compound classes (spirocyclic compounds, benzo-fused heterocyclic analogs) and a lead candidate (Q15).
• It includes concrete in vivo efficacy results at specific doses (10 mg/kg, 20 mg/kg, 40 mg/kg).
• The dataset is shared under a clear, standard license (CC-BY-NC-4.0).

Limitations

• The dataset is very small (5.4 KB), suggesting limited scope or a summary-level dataset.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale analysis.

Provenance

Source

figshare

Collection Method

Likely contains results from rational drug design and preclinical pharmacological studies.

Freshness

Last updated 2026-06-03 18:37:13; freshness should be verified.